Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.8352W HIGH $15.74
Volume
193.14 K
Value Traded
4.25 M
Short % Float
9.64%
Days to Cover
4.5
-1.08%Week
-1.61%1 Month
-1.88%3 Month
-52.59%6 Month
-34.43%5 Year
-54.69%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
279.63 M
EPS (TTM)
-1.11
P/E Ratio
-
Ent. Value
-39.59 M
Total Shares
76.30 M
Float Shares
73.73 M
Insiders
3.37%
Institutions
102.09%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
FULC Catalyst Timeline
Dated clinical, regulatory and corporate events for Fulcrum Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Fulcrum Therapeutics, Inc.
397Total events
11Upcoming
54Tier-1 (high impact)
2019 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲IND ClearanceSLTE-1009IND
SLTE-1009 received clearance to enter Phase 1 in Australia
migrainesource ↗
◆Trial InitiationPociredirTrial
Initiation of potential registration-enabling trial
sickle cell diseasesource ↗
▼Program DiscontinuationPociredirCorporate
Discontinued development of pociredir
sickle cell diseasesource ↗
◆Pipeline PrioritizationCorporate
Initiation of comprehensive strategic review to maximize stockholder value
▼Restructuring LayoffsCorporate
Initiation of efforts to significantly reduce operating expenses and preserve capital
◆Oral PresentationPociredirPresentation
Abstract accepted for oral presentation at Foundation for Sickle Cell Disease Research Symposium 2026
sickle cell diseasesource ↗
▼FDA Feedback ReceivedPociredirFDA Meeting
Received FDA meeting minutes regarding PRC2 complex risk
sickle cell diseasesource ↗
▼End Of Phase 2 MeetingPociredirFDA Meeting
End-of-phase interactions with FDA; meeting minutes received
sickle cell diseasesource ↗
◆Trial InitiationPociredirTrial
Plan to initiate potential registration-enabling trial
sickle cell diseasesource ↗
◆End Of Phase 2 MeetingPociredirFDA Meeting
End-of-Phase meeting with FDA; meeting minutes expected in Q2 2026
sickle cell diseasesource ↗
◆EU MAA SubmissionPociredirEx-US Regulatory
Engagement with EMA for protocol assistance
sickle cell diseasesource ↗
◆Oral PresentationPociredirPresentation
Conference call and webcast to discuss PIONEER results
sickle cell diseasesource ↗
▲Topline ReadoutPociredirClinical Data
Positive 12-week results from 20 mg dose cohort of Phase 1b PIONEER trial
sickle cell diseasesource ↗
◆Oral PresentationPresentation
Fulcrum Therapeutics management presentation at 44th Annual J.P. Morgan Healthcare Conference
◆Timing GuidancePociredirPresentation
Updated results from 20 mg cohort expected in Q1 2026
sickle cell diseasesource ↗
▲First Patient DosedPociredirTrial
First patient dosed in open-label long-term safety and durability trial
sickle cell diseasesource ↗
◆Topline ReadoutPociredirClinical Data
Cohort 4 (20 mg) updated results expected Q1 2026
sickle cell diseasesource ↗
▲Runway Guidance UpdateCorporate
Cash runway guidance: sufficient to fund operations into 2026
▲IND ClearanceSLTE-1009IND
SLTE-1009 clearance to enter Phase 1 clinical trials in Australia
migrainesource ↗
▼Equity OfferingCorporate
Pricing of upsized $175.0 million public offering of common stock and pre-funded warrants
◆Oral PresentationPociredirPresentation
Investor event to review new clinical data from PIONEER trial of pociredir
sickle cell diseasesource ↗
◆R&D DayPociredirPresentation
Fulcrum investor event at ASH 2025 featuring pociredir data
sickle cell diseasesource ↗
▲Topline ReadoutPociredirClinical Data
Positive initial results from 20 mg dose cohort of Phase 1b PIONEER trial
sickle cell diseasesource ↗
◆Poster PresentationPociredirPresentation
Pociredir Phase 1b PIONEER trial data presentation at ASH 2025
sickle cell diseasesource ↗
◆Poster PresentationPresentation
Preclinical data on calmodulin pathway modulator program for DBA at ASH 2025
diamond-blackfan anemiasource ↗
▲Oral PresentationPociredirPresentation
Positive initial results from 20 mg dose cohort presented at ASH 2025
sickle cell diseasesource ↗
◆Oral PresentationPociredirPresentation
Presentation of PIONEER trial data at ASH Annual Meeting
sickle cell diseasesource ↗
▲Enrollment CompletePociredirTrial
Enrollment completed for PIONEER Phase 1b trial
sickle cell diseasesource ↗
▲Topline ReadoutPociredirClinical Data
Initial results from 20 mg dose cohort (data cutoff Nov 11, 2025)
sickle cell diseasesource ↗
▲Enrollment CompletePociredirTrial
Enrollment complete in 20 mg dose cohort of PIONEER trial
sickle cell diseasesource ↗
◆Poster PresentationFTX-6274Presentation
Poster presentation of preclinical data for FTX-6274 at ESMO Congress 2025
castration-resistant prostate cancersource ↗
◆Topline ReadoutPociredirClinical Data
20 mg dose cohort data expected by end of 2025
sickle cell diseasesource ↗
●IND SubmissionIND
IND submission for DBA & Other BMFS planned
Diamond Blackfan Anemia & Other Bone Marrow Failure Syndromessource ↗
●Poster PresentationPociredirPresentation
Real-world data analysis accepted for publication at ASCAT 2025
sickle cell diseasesource ↗
▲Topline ReadoutPociredirClinical Data
12 mg Cohort 3b topline data disclosed
sickle cell diseasesource ↗
◆Oral PresentationPociredirPresentation
Topline results from 12 mg dose cohort of Phase 1b PIONEER trial
sickle cell diseasesource ↗
▲Topline ReadoutPociredirClinical Data
Positive topline results from 12 mg dose cohort of Phase 1b PIONEER trial
sickle cell diseasesource ↗
●Enrollment UpdatePociredirTrial
Cohort 4 (20 mg) enrollment open with N=6 enrolled as of July 25, 2025
sickle cell diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How FULC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-02-24 | Pociredir | Phase 1b data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 58%
Micro Cap(rank 381 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pociredir Small moleculeNCT05169580 | Sickle Cell Disease | Phase 2 | COMPLETED | 95 | Jan 20, 2026 | ||||||
| FTX-6058- Two Dosing Periods Small moleculeCompletedNCT04586985 | Sickle Cell Disease | Phase 1 | COMPLETED | 109 | Nov 15, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every FULC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pociredir Fast TrackOrphan | sickle cell disease | Phase 1b | 2026-02-24 | mean absolute hb F increase: 12.2%; baseline hb F: 7.1%; week 12 hb F: 19.3%Read More | Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| TANG KEVIN10% Owner | Buy | 50,945 7,080,945 held | $3.52 | 07/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in FULC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 1.2 % | 23.97 M | 6.55 M |
FULC Institutional Ownership Trends
FULC Short Interest
Shares sold short, counted twice a month.
9.64%
Short % of Float
of tradable shares sold short
7.1M
Shares Sold Short
-1.2% vs prior count
4.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How FULC ranks across every disease it competes in
Competitive Position is a premium feature
See how FULC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialFULC News
FULCFulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Fulcrum Therapeutics and Slate Medicines have announced a merger agreement to create a combined company focused on advancing innovative migraine therapies. The merger will facilitate the development of Slate's lead candidate, SLTE-1009, a monoclonal antibody for migraine prevention. Additionally, the companies secured $245 million in financing to support their operations and clinical trials through 2029.
Read more →FULC▼ -51.1%on this news
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
Fulcrum Therapeutics has announced the discontinuation of its pociredir program for sickle cell disease following FDA feedback regarding safety concerns. The decision was influenced by the observed risk of secondary malignancies linked to similar treatments. The company will now explore strategic alternatives to enhance stockholder value while managing its operating expenses.
Read more →FULCFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics granted non-statutory stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The company issued 55,500 options to purchase common stock at an exercise price of $7.02 per share. These options carry a ten-year term and vest over four years. The grant follows Nasdaq Listing Rule 5635(c)(4) requirements for inducements to new hires.
Read more →FULCFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
Fulcrum Therapeutics reported positive clinical data for pociredir, indicating significant fetal hemoglobin induction and improvements in anemia markers. The company plans to initiate a registration-enabling trial in late 2026 and has dosed the first patient in a long-term safety trial. Fulcrum's financial position remains strong with $333.3 million in cash, extending its runway into 2029.
Read more →FULCFulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
Fulcrum Therapeutics has appointed Dr. Josh Lehrer to its Board of Directors. Dr. Lehrer, a physician-scientist with over two decades of experience, previously led the development of Oxbryta for sickle cell disease. His expertise in rare disease drug development is expected to aid Fulcrum in advancing its pipeline, particularly the pociredir program.
Read more →FULCFulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET
Fulcrum Therapeutics has announced the release of its first quarter 2026 financial results, scheduled for April 27, 2026. A conference call and webcast will be held at 8:00 a.m. ET to discuss these results and provide updates on recent corporate developments. Interested participants can register online to access the call.
Read more →FULCMedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
Fulcrum Therapeutics, MedicAlert Foundation, and SCDAA have partnered to enhance emergency care for sickle cell disease patients. This collaboration aims to streamline access to patient-specific care plans during acute pain crises in emergency departments. By providing MedicAlert Smart Medical ID Cards, patients can ensure that critical health information is quickly available to clinicians, improving care coordination.
Read more →FULCFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Fulcrum Therapeutics will present at the Leerink Partners Global Healthcare Conference on March 10, 2025. The presentation will focus on their clinical-stage programs aimed at treating genetically defined rare diseases. A webcast of the event will be available, along with a replay for 30 days post-presentation.
Read more →FULC▼ -21.2%on this news
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
Fulcrum Therapeutics reported cash and securities of $352.3 million at the end of 2025. The company raised $164.2 million through a public offering in December. This funding extends its cash runway into 2029. Fulcrum plans to start a registration-enabling trial for pociredir in the second half of 2026.
Read more →FULC▼ -21.2%on this newsshared move
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics reported positive 12-week results from the 20 mg dose cohort of its Phase 1b PIONEER trial for pociredir in sickle cell disease. Mean absolute fetal hemoglobin increased by 12.2 percent, reaching 19.3 percent at Week 12. Seven of 12 patients achieved absolute hemoglobin levels of at least 20 percent. The drug was generally well-tolerated with no treatment-related serious adverse events.
Read more →FULCFulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics will present results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir, an investigational treatment for sickle cell disease. The conference call is scheduled for February 24, 2026, and will feature insights from Dr. Martin Steinberg. Pociredir has demonstrated positive effects on fetal hemoglobin levels and has received FDA designations.
Read more →FULC▲ +5%on this news
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 6, 2026
Fulcrum Therapeutics announced the grant of 70,000 stock options to a new employee as part of its 2022 Inducement Stock Incentive Plan. The options, priced at $10.72 per share, will vest over four years, reflecting the company's strategy to attract and retain talent. This move aligns with Fulcrum's focus on developing therapies for genetically defined rare diseases.
Read more →FULCJanuary 2026 Disclaimer and Notice This presentation contains “forward-looking statements” of Fulcrum Therapeutics, Inc. (Fulcrum or Fulcrum Therapeutics) within the meaning of the Private Securities Litiga
Fulcrum Therapeutics presented promising forward-looking statements regarding its blood disease treatment, pociredir, which is aimed at enhancing fetal hemoglobin production in sickle cell disease (SCD) patients. The data from initial cohorts show robust hemoglobin improvements and received designations favoring its regulatory review. However, the company acknowledges that clinical uncertainties and ongoing risks must be carefully managed as the therapy progresses through trials and regulatory pathways. Additionally, Fulcrum's financial outlook appears stable, extending cash runway into 2029.
Read more →FULCFulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Fulcrum Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will highlight their focus on developing small molecules for genetically defined rare diseases, particularly their lead program aimed at treating sickle cell disease. A live webcast will be available for those interested in the presentation.
Read more →FULC▼ -5.5%on this news
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Fulcrum Therapeutics announced the pricing of an upsized public offering to sell 11,851,853 shares of common stock at $13.50 per share, alongside pre-funded warrants for $13.499 each. The total anticipated proceeds from the offering are around $175 million, which will support various corporate activities, particularly research and development. The offering, managed by notable financial institutions, is subject to customary closing conditions and is expected to finalize soon.
Read more →FULC▲ +46%on this news· ran to +64% by day 1shared move
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Fulcrum Therapeutics announced positive initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease. The trial showed a significant increase in fetal hemoglobin levels, with 58% of patients achieving levels of 20% or higher. Pociredir was well-tolerated, with no serious adverse events reported. The company plans to provide further updates in Q1 2026.
Read more →About Fulcrum Therapeutics, Inc.
Headquarters26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
BIOPHARMAWATCH ELITE PLUS
Trade the next FULC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime